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The nucleoside(tide) reverse transcriptase inhibitors (NRTIs) have traditionally been an important ‘back-bone’ of an
antiretroviral therapy (ART) regimen. However all agents have been associated with both short- and long-term toxicity.
There have also been concerns regarding the efficacy and safety of a treatment sequencing strategy in which those
with past exposure and/or resistance to one or more NRTIs are re-exposed to ‘recycled’ NRTIs in subsequent
ART regimens. Newer, potent and possible safer, agents from various ART classes continue to become available.
There has therefore been growing interest in evaluating NRTI-sparing regimens. In this review, we examined studies of
NRTI-sparing regimens in adult HIV-positive patients with varying degrees of ART experience. We found that in
treatment experienced patients currently on a failing regimen with detectable viral load, there now exists a
robust evidence for the use of NRTI-sparing regimens including raltegravir with a boosted-protease inhibitor
with or without a third agent. In those on a virologically suppressive regimen switching to a NRTI-sparing
regimen or in those ART-naïve patients initiating an NRTI-sparing regimen, evidence is sparse and largely
comes from small exploratory trials or observational studies. Overall, these studies suggest that caution needs to be
exercised in carefully selecting the right candidate and agents, especially in the context of a dual-therapy regimen, to
minimise the risks of virological failure. There is residual toxicity conferred by the ritonavir boost in protease-inhibitor
containing NRTI-sparing regimens. Fully-powered studies are needed to explore the place of N (t)RTI-sparing regimens
in the sequencing of ART. Additionally research is required to explore how to minimise the adverse effects associated
with ritonavir-based pharmacoenhancement.
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The nucleoside(tide) reverse transcriptase inhibitor (NRTI)
class has formed the ‘back-bone’ of antiretroviral therapy
(ART) regimens since the early ART era. All major treat-
ment guidelines currently recommend the selection of
2 NRTIs and a third agent from a separate class in
the initial management of ART naïve HIV-positive pa-
tients; some guidelines suggest recycling NRTI agents
as far as possible in ART-experienced HIV-positive pa-
tients experiencing virological failure [1-4]. However, con-
cerns about long-term toxicities and cross–resistance
within the NRTI class combined with the continuing de-
velopment of newer, seemingly safer agents in several* Correspondence: aachhra@kirby.unsw.edu.au
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article, unless otherwise stated.independent classes of drugs has led to a growing interest
in the potential use of feasible, innovative and appealing
NRTI-sparing options.
The main purpose of this review is to explore the
current state of our knowledge on the efficacy and safety
of NRTI class-sparing antiretroviral regimens used in
the management of adult HIV-positive patients. The
review is restricted to studies conducted on adult HIV-1
mono-infected individuals published in the English lan-
guage. The review has a greater focus on studies published
since 2006 (so as to ensure relevance to contemporary
practice). We included clinical trials as well as non-
randomised small clinical studies, both published and
unpublished (conference presentations).ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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The thymidine analogue NRTIs, such as zidovudine and
in particular stavudine (d4T) have been associated with
serious mitochondrial toxicity which has been linked to
lipoatrophy. In addition, zidovudine has been associated
with anaemia and didanosine with peripheral neuropathy.
As a consequence these agents are no longer recom-
mended as preferred components of therapy; in the case
of stavudine it has been recommended that it’s use be
phased out, even in low- and middle-income countries
[2]. However, one of the most important push factors for
the assessment of NRTI-sparing regimens has been a
growing understanding of the long-term toxicity profile of
even the newer, relatively safe NRTIs in common use such
as tenofovir and abacavir. Tenofovir has been associated
with nephrotoxicity, including acute and chronic renal
failure, proximal tubular dysfunction, nephrogenic dia-
betes insipidus and nephrotic syndrome [1,4,5]. In a large
EuroSIDA cohort study, tenofovir use was associated with
a 20% increased risk of chronic kidney disease [6]. Further,
clinical trials and observational studies have consistently
demonstrated decline in bone-mineral density (BMD) of
about 2-10% in the short-term attributable to the use of
tenofovir [7,8]. Cumulative use of tenofovir has been asso-
ciated with a higher risk of osteoporotic fracture [9]. Fi-
nally, one observational study attributed increased risk of
heart failure to the tenofovir use, although this observa-
tion has not been replicated [10]. Abacavir, another com-
monly used NRTI has been implicated in the risk of
myocardial infarction by some large cohort studies and a
clinical trial [10-12]. However, the evidence is not defini-
tive as this association has not been seen in other studies
[13]. Nevertheless, it has generated considerable anxiety in
the provider community, especially for its use in patients
with a high cardiovascular risk. Further, abacavir is associ-
ated with the risk of severe hypersensitivity reactions
which can only be eliminated by screening out those car-
rying the HLA-B57*01 allele [1,14].
One of the main concerns prompting studies on NRTI-
sparing regimens in failing patients has been that of
possible reduced potency of NRTI agents due to current
or archived nucleoside mutations such as thymidine
analogue associated mutations (TAMs). As a result, if
NRTIs are being recycled in such patients, they could po-
tentially be exposed to a regimen with <2 or 3 fully-active
agents. This is especially of concern in resource limited
settings where NRTIs are recommended for recycling
following treatment failure identified through immuno-
logical or virological failure. This surrogate means of iden-
tifying virological failure is associated with substantial
degrees of resistance which may significantly compromise
the action of recycled NRTIs in future ART regimens
[15]. Moreover, access to agents beyond NRTIs and the
ritonavir-boosted protease inhibitors atazanavir, lopinavirand darunavir is limited [2]. Switching a specific anchor
agent to one with a lower genetic barrier (e.g. LPV/r re-
placed by raltegravir [16] or PI replaced with another
NRTI [17]) with a compromised NRTI backbone could re-
sult in higher rates of treatment failure. Finally, recycling
NRTIs might mean exposing patients to long term NRTI
agents which may result in unanticipated, cumulative ad-
verse effects.
Several newer agents from various classes with a good
safety profile to date continue to become available. These
include new integrase inhibitors, newer non-nucleoside
reverse transcriptase inhibotors (NNRTIs, e.g. etravirine
and rilpivirine), the CCR5 attachment inhibitor maraviroc
and the PIs lopinavir, darunavir and atazanavir. It is there-
fore possible to construct regimens containing 2-3 fully-
active agents which are NRTI-sparing.
We next discuss NRTI-sparing regimens that have been
evaluated in each of the three main types of patient popu-
lations: treatment-experienced failing patients where most
of the evidence is concentrated; virologically suppressed
patients; and ART-naïve patients.
NRTI-sparing regimens in treatment-experienced failing
patients
Recent large clinical trials have evaluated NRTI-sparing
regimens in treatment experienced patients experiencing
virological failure (key studies summarised in Table 1
[18-25]). The regimen most of interest has been that of
a boosted-PI with raltegravir, and/or maraviroc and/or
etravirine.
The SECOND-LINE study (n=541) [18] evaluated
ritonavir-boosted lopinavir (LPV/r) with raltegravir vs.
LPV/r + NRTIs (the WHO standard of care of recycling
NRTIs in HIV-positive patients with demonstrable viro-
logical failure of first-line NNRTI-based ART), with no
previous PI or integrase inhibitor exposure. The use of
resistance testing at randomization was optional. Of the
492 patients with resistance tests available, 89% had ≥1
NRTI mutations and 60% had M184V with ≥NRTI mu-
tations at baseline. Patients were randomised (stratified by
baseline HIV RNA ≤ or > 100,000 copies/mL) to receive
LPV/r with raltegravir or LPV/r with physician-chosen
NRTIs. At 48 weeks, the NRTI-sparing raltegravir arm
was non-inferior to the NRTI-containing control arm for
the primary endpoint of virological control <200 copies/
mL with an overall 81.7% virological response rate. The
NRTI control-arm resulted in a 2-4% greater decline in
BMD compared to the NRTI-sparing arm (likely due to
patients switching to tenofovir) [25]. On the other hand
the raltegravir arm was associated with a greater degree of
hypercholesterolaemia. Despite this there was no differ-
ence in the resultant total: HDL cholesterol ratio. Finally,
emergence of PI mutations was negligible in those experi-
encing virological failure, attesting to the high genetic
Table 1 Key recent studies of NRTI-sparing regimens in treatment experienced patients
Author, name of the trial,
if any/year/published?
Design Comparison N Follow-up
(weeks)
Results




(i) LPV/r + RAL vs. (ii) LPV/r +
recycled NRTIs in those failing
1st line NNRTI-based ART
541 (271 vs.
270)
48 -Arm (i) non-inferior to arm (ii) for
virological outcome
-No major differences in serious
adverse events
-Greater decline in BMD in arm (ii) [25]




(i) LPV/r + RAL (i) 433; (ii) 418;
(iii) 426
96 -Arm (i) non-inferior to arm (iii) for a
composite of virological and clinical
endpoint(ii) LPV/r monotherapy after
induction with LPV/r + RAL
(iii) LPV/r + recycled NRTIs
(control) in those failing 1st line
NNRTI-based ART
-Arm (ii) inferior to other arms for
virological outcome and higher
LPV/r resistance
-No differences in grade 3/4 events











-No differences in grade 3/4 events
-Higher mortality in arm (ii).





DRV/r + ETV in failing patients





48 -100% of ART naïve and 87% of
failing patients achieved virological
success.
-2 patients developed ETV mutations
and none had DRV mutations.
Imaz et al. [21]/2011/Yes Observational Salvage regimen of at least three
active agents from DRV, ETV, RAL
and MVC, with or without NRTIs
122 48 -78% virologically suppressed
(equal in both arms)
-Higher baseline viral load associated
with worse outcomes.
Nozza et al. [22]/2011/Yes Observational Salvage regimen of RAL +MVC +
ETV
28 96 -96% virologically suppressed
(<50 copies/ml)
Florence et al. [23]/2010/Yes Observational Salvage regimen of ETV+ optimised
regimen, 40% without NRTIs
941 24 -70% and 90% had viral load <50
and 400 copies/mL respectively.
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virological monitoring.
The EARNEST study [19] was similarly designed to
SECOND-LINE and performed in an identical patient
population (with an additional arm of LPV/r mono-
therapy after a 12 week induction combined with ral-
tegravir). After 96 weeks of follow-up the investigators
found no difference between the raltegravir and NRTI-
arms in the study’s primary composite endpoint of “good
disease control” (i.e. alive with no WHO stage 4 disease,
CD4 >250/mm3 and viral load <10,000 or >10,000 copies/
mL with no PI mutations), as well as virological outcome
(viral load <200 or <50 copies/mL). The investigators also
found no difference in grade 3/4 events at 96-weeks
follow-up. Of note, the monotherapy arm was found to be
virologically inferior to the control and LPV/r plus ralte-
gravir arms.
The OPTIONS study [20] was conducted on a set of
treatment experienced patients failing a PI-based regi-
men and with past exposure to NRTIs and NNRTIs(n=360). Patients were randomised to either NRTI-
including or NRTI-excluding optimised regimen arms
containing >2 fully active agents (not including NRTIs).
In the NRTI-sparing arm, the most common regimens
were raltegravir with boosted-darunavir (DRV/r) and ei-
ther etravirine (56%), maraviroc (14%) or both (9%). At
1 year of follow-up, virological suppression rates were
similar in both arms. Of note, the study only had the
power to find a non-inferiority margin of 15%. Finally,
though there were no major differences in the grade 3/4
safety outcomes the NRTI-arm experienced greater mor-
tality. It is unclear if causes of deaths were NRTI-related.
A few smaller observational studies confirm these find-
ings in routine clinic settings (Table 1). In one study of
122 patients with prior triple-class failure, the regimen of
raltegravir with DRV/r and maraviroc or etravirine dem-
onstrated similar virological efficacy (>75%) compared to
those using NRTI agents at 48 weeks [21].
Collectively, these studies confirm that in virologically
failing patients, the strategy of selecting 2 or 3 fully-active
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Of note, all of these studies have included a boosted-PI,
and because of their high genetic barrier to resistance,
the data should not be extrapolated to other 2-class
regimens. Also, recycled NRTI agents seem to retain effi-
cacy (i.e. non-inferior to the comparator arms), which
is reassuring in settings where newer agents are not
yet widely available.
NRTI-sparing regimens in patients receiving suppressive
ART
Switching to a NRTI-sparing regimen in a virologically
suppressed patient needs consideration of several factors.
These include the treatment history, archived mutations,
duration of viral suppression, expected level of adherence,
the choice of agents as well as the patient motivation to
switch from a stable regimen. Large, well powered trials
in such patients are few and difficult to recruit, although
several smaller studies have identified promising regimens.
Key studies on this patient population are summarised in
Table 2 [26-36].
In the ACTG 5116 trial [34], virologically suppressed
patients receiving a standard PI- or NNRTI-based ART
regimen were randomised to efavirenz with LPV/r or
efavirenz with NRTIs (standard ART arm). Though not a
fully powered trial, the NRTI-sparing arm performed
poorly due largely to higher rates of discontinuation and
toxicity as well as dyslipidemia. This study suggests that
the choice of agents will be important in constructing
such regimens as they will need to provide clear evi-
dence of greater safety before convincing ART providers
and/or patients to consider a switch.
In a more recent small exploratory study (the KITE
trial [31]), virologically suppressed patients with no his-
tory of failure to PI-based regimens were randomised to
standard ART (n=20) or LPV/r with raltegravir (n=40).
At 42 weeks, there were no differences in virological sup-
pression rates (90-92%) and no treatment limiting side
effects, although there was a trend for higher triglycerides
in the NRTI-sparing arm. Another similar exploratory
single-arm trial [33] (n=29) reported similar results with
raltegravir plus a boosted-PI (mainly darunavir) regimen
with no serious dyslipidaemia at 24 weeks.
Since most studies on NRTI-sparing regimens have in-
cluded a boosted-PI regimen, residual toxicity concerns
with ritonavir as the booster (such as gastrointestinal
upset and dyslipidemia) have been seen as a relative dis-
advantage. With several new agents now available, it is
now possible to conceive regimens which exclude not
only NRTIs but also ritonavir, as well as first-generation
NNRTIs such as efavirenz (also associated with dyslipidae-
mia and neurotoxicity) or nevirapine. This strategy is es-
pecially attractive in virologically suppressed patients with
minimal treatment experience, where good adherence canbe presumed and the possible adverse impact of high viral
load on regimen efficacy is less of a concern.
In one recent cohort study on treatment experienced,
virologically suppressed patients switching to dual therapy
of etravirine with raltegravir, 91% maintained virological
suppression at 48 weeks [36]. In another exploratory ob-
servational study of 62 patients (the majority with HIV
RNA <400 copies/mL) switching to NRTI-sparing regi-
mens, 92% had undetectable viral loads at 42 months
[26]. The most common regimens used were: raltegra-
vir, unboosted atazanavir, and maraviroc (33%); raltegravir
and unboosted atazanavir (22%); raltegravir, maraviroc,
and etravirine (13%). Of note, 3 out of 15 people re-
ceiving a two drug regimen demonstrated low-level viremia
(i.e. >50 but <200 copies/mL), the clinical meaning of
which is debated. In another study, called No Nuc No
Boost [29], ART-naïve R5 tropic patients with high CD4
counts and baseline viral load <103 log copies/mL were
first treated with tenofovir/emtricitabine, raltegravir and
maraviroc for six months after which those with plasma
viral load <50 copies/mL at 24 weeks were continued on a
two-drug combination of raltegravir and maraviroc for a
further 24 weeks. All patients retained viral load <50 cop-
ies/mL on dual therapy. However, in another similar study
(RocNRaL) on more treatment experienced patients, this
dual regimen demonstrated lower efficacy [28]. Collect-
ively, these studies suggest that while such unconventional
regimens are promising in carefully selected patients, cau-
tion must be exercised when using dual therapy regimens
without the support of a high genetic barrier to the selec-
tion of resistance like LPV/r or DRV/r.
Boosted-PI monotherapy
Given the high genetic barrier of boosted PIs, several
large studies have evaluated this simplification strategy.
Boosted-PI monotherapy trials have been extensively
reviewed previously [37,38] and are therefore not cov-
ered in detail here. In the 96-week trial of LPV/r mono-
therapy in virologically suppressed patients receiving a
boosted-PI + NRTI regimen with no history of failure
(OK trial), although the virological success rate was
similar, the monotherapy arm had a significantly higher
rate of low-level viremia (12%) necessitating reinduction
with NRTIs [39]. A similar trial with DRV/r monother-
apy (MONET) [40] also demonstrated a high virological
success rate with DRV/r however the monotherapy arm
had a higher rate of low-level viremia. Overall, although
the virological response rates in LPV/r or DRV/r mono-
therapy arms are high and PI mutations are rare in the
setting of regular virological monitoring, there appears
to be a greater risk of consistent low-level viremia which
may herald virological failure in the monotherapy arms.
In the fully powered EARNEST study [19] described
above, the PI monotherapy arm (combined for the first
Table 2 Key recent studies of switch to NRTI-sparing regimens in virologically suppressed patients on standard ART
Author, name of the trial,
if any/year/published?
Design Comparison N Follow-up
(weeks)
Results
Monteiro et al. [36]/2013/Yes Observational RAL + ETV 25 48 -91% virologically suppressed in
per-protocol analysis
-Lipids improved
Ward et al. [26]/2013/No Observational Switching for toxicity concerns to a RAL
+ 1 or 2 agents, most commonly on
RAL + ATV/r with or without ETV or MVC
62 168 -92% virologically suppressed;
-3 of 15 on dual therapy had to add
third agent for low-level viremia
Calin et al. [27]/2013/No Observational Switching to RAL + ETV regimen 91 48 -93% had viral load <50 copies/mL
-4/5 with virological failures had past
NNRTI mutations
-3 patients had RAL mutations




R5-trophic suppressed patients switched
to MVC + RAL
41 48 -Failure in 11.4%
-RAL mutations in 3/5 patients who
failed
-1/5 had R5 to ×4 virus switch




MVC + RAL 10 48 -No virological failures (>50 copies/mL)
-No serious adverse event
Burgos et al. [30]/2012/No Observational Switching for toxicity concerns to a
PI/r + 2nd agent, many with no NRTI
131 56 - > 90% virologically suppressed.




(i) LPV/r + RAL; (ii) standard ART 60 48 -92% in arm (i) and 88% in arm (ii)
with viral load <50 copies/mL;
-Higher triglycerides in arm (i)
-No difference in BMD or body
composition.




Patients receiving ATV/r randomized to:
(i) ATV/r (300/100 mg respectively once






(ii) ATV (300 mg twice daily) + RAL
(400 mg twice daily)
-All patients remained virologically
suppressed
Cordery et al. [35]/2010/Yes Observational RAL + ATV (unboosted) 20 72 -Only 1 (5%) failure
Allavena et al. [33]/2009/Yes Observational Switching for toxicity concerns to a
PI/r + RAL.
29 48 -100% virologically suppressed
Fischl et al. [34]/2007/Yes RCT, not fully
powered
(i) LPV/r + EFV; 236 96 -Arm (i): shorter time to failure or
discontinuation;
(ii) EFV + NRTIs
-Arm (i): greater increase in
triglycerides
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to be significantly inferior to the standard ART arm. The
authors concluded that such a strategy is unsuitable for
a public health approach. Presently, none of the major
treatment guidelines recommend PI monotherapy be-
cause of concerns regarding efficacy [1-4].
NRTI-sparing regimens in ART naïve patients
Large, fully powered trials evaluating NRTI sparing
regimens in ART naïve patients are few and most
smaller studies have suggested that care must be exer-
cised in selecting both suitable agents and candidates
for such regimens. Key studies are summarised in
Table 3 [41-48].The ACTG 5142 trial randomised ART-naïve patients
to standard ART arms with LPV/r or efavirenz, both
given with investigator selected 2NRTIs and a NRTI-
sparing arm of LPV/r and efavirenz [46]. Though the
NRTI-sparing arm showed comparable virological effi-
cacy overall at 96 weeks, it performed poorly in those
with baseline viral load >100,000 copies/mL and the rate
of discontinuation due to adverse events was significantly
higher than other two arms. Of note, the dose of LPV/r
was increased due to its interaction with efavirenz, which
may have contributed to the additional toxicity in this
arm.
More recent pilot studies have explored a dual therapy
regimen of raltegravir with a boosted-PI. These studies
Table 3 Key recent studies of switch to NRTI-sparing first-line ART regimens in ART naïve patients
Author, name of the trial,
if any/year/published?
Design Comparison N Follow-up
(weeks)
Results
Mills et al. [41],
A4001078/2013/Yes
RCT, phase-2b pilot (i) MVC + ATV/r 121 48 -75% in arm (i) and 84% in arm (ii) had viral load <50
copies/mL.
(ii) TDF + FTC + ATV/r
-More hyperbilirubenmia in arm (i)
-Nine in arm (i) and 3 in arm (ii) had low-level viremia
after virological suppression
Reynes et al. [42],
PROGRESS/2013/Yes
RCT pilot study (i) LPV/r + RAL (i) 101;
(ii) 105
96 -66.3% in arm (i) and 68.6% in arm (ii) responded by
FDA-TLOVR
(ii) LPV/r + TDF + FTC
-Better body comp in arm (i)
-Greater decline in eGFR in arm (ii)
Kozal et al. [47],
SPARTAN/2012/Yes
RCT pilot study (i) ATV + RAL (i) 63;
(ii) 31
24 -74.6% in arm (i) and 63.3% in arm (ii) had viral load <50
copies/mL
(ii) ATV/r + TDF + FTC
-4/6 failures in arm (i) had RAL mutations.
-20% incidence of grade-4 hyperbilirubenimia in arm (i).
Taiwo et al. [43,48],
MIDAS/2013/Yes
Single-arm pilot MVC + DRV/r 25 96 -Viral load < 50 copies/mL: 8.3% and 10% at week 48
and 96, respectively.
-Virological failures mainly explained be high baseline
viral load >100000 copies/mL
Bedimo R et al. [44],
RADAR/2011/No
RCT pilot (i) RAL + DRV/r 80 24 -86% in arm (i) and 87% in arm (ii) had viral load
<50 copies/mL
(ii) DRV/r + TDF + FTC
Taiwo et al. [45],
ACTG5262/2011/Yes
Single-arm pilot DRV/r + RAL 112 48 -26% with viral load > 50 copies/mL, majority with
low-level viremia (<200 copies/mL)
-Baseline viral load >100000 copies/mL strongly
associated with failure
Riddler et al. [46],
ACTG5142/2008/Yes
RCT (i) EFV + NRTIs (i) 250 96 -89%, 77% and 83% had viral load <50 copies/mL in
arms (i), (ii) and (iii) respectively
(ii) LPV/r + NRTIs (ii) 253
(iii) LPV/r + EFV (iii) 250
-No difference in time to toxic effects
-At failure, resistance mutations more common in arm (iii)
NOTE for Tables 1, 2, 3: ATV/r = ritonavir boosted atazanavir, DRV/r = ritonavir boosted darunavir, LPV/r = ritonavir boosted lopinavir, RAL = raltegravir, ETV =
etravirine, MVC =maraviroc, EFV = efavirenz, TDF = tenofovir, FTC = emtricitabine, NRTI = Nucleoside(tide) reverse transcriptase inhibitors, PI = protease inhibitors.
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versely impact the success of the regimen in such pa-
tients. In a single arm study of 112 patients receiving
raltegravir and DRV/r, virological failure (>50 copies/mL)
was 26% at 48 weeks [45]. Most (21/28) of the patients
with virological failure and all of those with integrase mu-
tations had a baseline plasma viral load >100,000 copies/
mL . Almost 50% of failures were that of low level viremia
(>50 but <200 or <400 copies/mL). No PI mutations were
detected. However, the similar fully-powered trial of DRV/
r + RAL (NEAT protocol 001, see below) is ongoing and
has not been stopped by Data Safety Monitoring Board. In
the RADAR study (small randomised study of DRV/r with
either raltegravir or NRTIs), response rates were poorer
in the raltegravir arm which also experienced higher
rates of dyslipidemia [44]. In the SPARTAN pilot
study evaluating experimental unboosted atazanavir(300 mg) with raltegravir (vs. NRTI with boosted-
atazanavir), most raltegravir resistance mutations oc-
curred in those with baseline viral load >100,000
copies/mL [47]. Also, the rate of hyperbilirubinemia
in the raltegravir arm was higher (possibly due to the
higher dose of atazanavir used in that arm (300 mg
bid) and the known pharmacoenhancement effect of
RAL on ATV) [47]. In a randomised study of LPV/r
with raltegravir or with NRTIs (PROGRESS trial),
virological response did not differ by baseline viral
load although there were only a few patients with
high viral load at baseline [42]. Of note, in this study,
surrogate renal and bone outcomes were significantly
more favourable in the NRTI-sparing arm.
Overall, these studies suggest that while NRTI-sparing
regimens are promising, caution needs to be exercised in
the selection of patients. In particular, the impact of the
Achhra and Boyd AIDS Research and Therapy 2013, 10:33 Page 7 of 9
http://www.aidsrestherapy.com/content/10/1/33baseline plasma viral load on regimen efficacy and the
risk of baseline or archived resistance mutations for fail-
ure need further study. Dual-therapy regimens in general
have resulted in mixed results. Well designed, appropri-
ately powered randomised controlled trials are required
to reach definitive conclusions. In a recent well-powered
trial of LPV/r with lamivudine (a relatively safe NtRTI) vs.
LPV/r+2 NRTIs, the dual therapy arm demonstrated non-
inferior efficacy of >85% at 48 weeks regardless of baseline
viral load, with fewer toxicity-related discontinuations
[49]. This study indicates that carefully selected dual ther-
apy could be a reasonable option even in ART-naïve pa-
tients. Of note, however, dyslipidemia tended to be more
pronounced in the dual therapy arm, which may be due to
the absence of tenofovir which is known to be associated
with a favourable lipid profile [50,51]. On the other hand,
the MODERN study – a well powered study of mara-
viroc + DRV/r vs. standard ART (n=791) was prematurely
stopped at 48 weeks due to inferior performance of the
dual-therapy arm (unpublished data) [52]. Ongoing stud-
ies such as A4001095 (DRV/r with maraviroc or NRTIs)
(Trial Identifier: NCT01345630)and the NEAT protocol
001/ ANRS 143 (DRV/r with raltegravir or NRTIs) (Trial
Identifier: NCT01066962) should provide a clearer un-
derstanding of the use of such regimens in ART-naïve
patients.
Limitations, conclusions and future directions
NRTI-sparing regimens appear to be promising and if
established, will be an important step towards opti-
mising ART to maximise patient safety. However, there
are a few important points to consider. First, trials
evaluating such regimens will need to show a clear
benefit in terms of long-term safety so as to convince
clinicians to move away from much more familiar
NRTI-based regimens. Promising regimens such as
the use of a boosted-PI with raltegravir have shown a
higher risk of dyslipidemia in some studies likely at-
tributable to ritonavir and possibly the absence of
tenofovir. Future studies considering regimens without
NRTIs, ritonavir and efavirenz (due to neuro-psychaitric
adverse events) will be important in identifying safer,
better tolerated ART regimens. A recent study by our
group suggested that most HIV-positive patients will
have such regimen options available to them regard-
less of their treatment experience [53].
In addition, most clinical trials follow participants up
for 48 to 96 weeks, which, along with their enrolment
number, is not of sufficient duration to demonstrate dif-
ferences in hard clinical endpoints such as renal failure
or fractures. Cohort studies will be instrumental in this
regard. Also, most of the studies are small and unpub-
lished. Better quality evidence is therefore clearly needed
in this area.Second, many of the studies on NRTI-sparing two drug
regimens suggest that in selected patients (e.g. those with
high baseline viral loads), the risk of virological failure and
selection of resistance mutations to the non-PI compo-
nent are a risk. This suggests that such regimens, espe-
cially ones without a boosted-PI support, should ideally be
first evaluated in virologically suppressed patients.
Finally, many NRTI-sparing regimens are may require
twice daily dosing frequency and ≥1-2 pills/day. This
may impact the adherence (example selective lower ad-
herence to the 2nd dose of raltegravir in DRV/r + ralte-
gravir regimen). However, both etravirine and maraviroc
have pharmacokinetic and clinical data supporting
once-daily dosing [41,54], and RAL is being studied in a
1200-mg once-daily formulation. Therefore, NRTI-sparing
once-daily regimens could be possible in future.
In conclusion, there has now accumulated a sizeable
evidence base that supports the use of NRTI-sparing
regimens of 2–3 fully-active agents for HIV-positive pa-
tients currently on a failing ART regimen. For virologic-
ally suppressed patients, an NRTI-sparing regimen may
be an option is some patients although further, more de-
finitive studies are needed. Finally, the evidence is sparse
for such regimens in the ART naïve patient population
and more research is required to generate robust evi-
dence. Future studies such as A4001095 and NEAT
protocol 001/ ANRS 143 will be instrumental in inform-
ing the evidence base for such regimens.
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